<DOC>
	<DOCNO>NCT01678794</DOCNO>
	<brief_summary>To advance understanding mechanism human cardiorenal syndrome emphasis upon interaction diuretic therapy renal-angiotensin-aldosterone -system cGMP pathway . The belief chronic AT1 receptor blockade subject compensate CHF renal dysfunction improve renal function increase sodium excretion , glomerular filtration rate effective renal plasma flow renal function reserve compare response placebo-treated subject .</brief_summary>
	<brief_title>CR Aim # 2 - AT1 Receptor Blockade &amp; ACE Inhibition Effect Humoral Function</brief_title>
	<detailed_description>IRB # 09-003284 , `` Specific Aims 2 : Define human compensate CHF renal dysfunction , modulate action chronic AT1 receptor blockade addition ACE inhibition cardiorenal humoral function '' , involve 12 week study drug ( Candesartan placebo ) start 4 mg daily double every 2 week 16 mg , tolerate . Safety labs perform one week dose increase ( end week 1 , 3 5 ) , week 10 study . Participants monitor blood pressure weekly , aware watch symptom hypotension ( lightheadedness , dizziness , blur vision ) . Renal clearance test ECHO perform start end 12 week study medication 5-Domitilla Clinical Research Unit .</detailed_description>
	<mesh_term>Cardio-Renal Syndrome</mesh_term>
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<criteria>Left ventricular ejection fraction equal le 40 % assessed echocardiography , nuclear scan , MRI leave ventriculogram within past 48 month . Stable New York Heart Association ( NYHA ) class II III symptom define : change NYHA symptom past 3 month , stable dos ACE inhibitor , beta blocker , digoxin furosemide last 4 week episode decompensated CHF past 6 month . Calculated creatinine clearance equal le 80 ml/min great 20 ml/min , use MDRD formula assess within past 48 month confirmatory calculate creatinine clearance equal le 80 ml/min great 20 ml/min time enrollment . Subjects already take AT1 receptor blocker exclude . Aldosterone antagonist , antiarrhythmic medication vasodilator allow ; however , medication must stable dos 4 week prior enrollment . Subjects take nonsteroidal antiinflammatory drug ( NSAIDs ) except aspirin able increase medication dose duration study . Subjects exclude prior diagnosis intrinsic renal disease , include renal artery stenosis &gt; 50 % , meet one exclusion criterion list . Prior diagnosis intrinsic renal disease include renal artery stenosis &gt; 50 % Peritoneal hemodialysis within 90 day anticipation dialysis ultrafiltration form require study period Hospitalization decompensated CHF past 6 month Subjects take AT1 receptor blocker Myocardial infarction within 6 month screen Unstable angina within 6 month screen , evidence myocardial ischemia Significant valvular stenosis , hypertrophic , restrictive obstructive cardiomyopathy , constrictive pericarditis , primary pulmonary hypertension , biopsy proven active myocarditis Severe congenital heart disease Sustained ventricular tachycardia ventricular fibrillation within 14 day screen Second third degree heart block without permanent cardiac pacemaker Stroke within 3 month screen , evidence significantly compromise CNS perfusion ALT &gt; 1.5 time upper limit normal Serum sodium &lt; 125 mEq/dL &gt; 160 mEq/dL Serum potassium &lt; 3.5 mEq/dL &gt; 5.7 mEq/dL Serum digoxin level &gt; 2.0 ng/ml Hemoglobin &lt; 9 gm/dl Other acute chronic medical condition laboratory abnormality may increase risk associate study participation may interfere interpretation data Received investigational drug within 1 month prior dose Patients allergy iodine . Female subject pregnant breastfeeding In opinion investigator , unlikely comply study protocol unsuitable reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Chronic heart failure ( CHF )</keyword>
	<keyword>cardiac renal dysfunction</keyword>
</DOC>